AmericanJournalofEpidemiology Vol.175,No.4
ªTheAuthor2012.PublishedbyOxfordUniversityPressonbehalfoftheJohnsHopkinsBloombergSchoolof DOI:10.1093/aje/kwr318
PublicHealth.Allrightsreserved.Forpermissions,pleasee-mail:journals.permissions@oup.com. AdvanceAccesspublication:
January6,2012
Original Contribution
Mortality Among Young Injection Drug Users in San Francisco: A 10-Year
Follow-up of the UFO Study
Jennifer L.Evans*,Judith I. Tsui, JudithA. Hahn,Peter J.Davidson, Paula J. Lum, and
KimberlyPage
*CorrespondencetoJenniferL.Evans,PreventionandPublicHealthGroup,DepartmentofEpidemiologyandBiostatistics,
UniversityofCalifornia,SanFrancisco,50BealeStreet,Suite1200,SanFrancisco,CA94105(e-mail:jevans@epi.ucsf.edu).
InitiallysubmittedMarch18,2011;acceptedforpublicationAugust16,2011.
This study examined associations between mortality and demographic and risk characteristics among young
injectiondrugusersinSanFrancisco,California,andcomparedthemortalityratewiththatofthepopulation.Atotal
of644young(<30years)injectiondruguserscompletedabaselineinterviewandwereenrolledinaprospective
cohortstudy,knownastheUFO(‘‘UFindOut’’)Study,fromNovember1997toDecember2007.UsingtheNational
Death Index, the authors identified 38 deaths over 4,167 person-years of follow-up, yielding a mortality rate
of 9.1 (95% confidence interval: 6.6, 12.5) per 1,000 person-years. This mortality rate was 10 times that of
the general population. The leading causes of death were overdose (57.9%), self-inflicted injury (13.2%),
trauma/accidents (10.5%), and injection drug user-related medical conditions (13.1%). Mortality incidence was
significantly higher among those who reported injecting heroin most days in the past month (adjusted hazard
ratio ¼ 5.8, 95% confidence interval: 1.4, 24.3). The leading cause of death in this group was overdose, and
primaryuseofheroinwastheonlysignificantriskfactorfordeathobservedinthestudy.Thesefindingshighlight
thecontinuedneedforpublichealthinterventionsthataddresstheriskofoverdoseinthispopulationinorderto
reduceprematuredeaths.
drugusers;epidemiology;hepatitisC;mortality;overdose;youngadult
Abbreviations:CI,confidenceinterval;HBV,hepatitisBvirus;HCV,hepatitisCvirus;HIV, humanimmunodeficiencyvirus;
ICD,InternationalClassificationofDiseases;IDU,injectiondruguser;IQR,interquartilerange;IRR,incidencerateratio;NDI,National
DeathIndex;UFO,‘‘UFindOut.’’
Injectiondrugusehasbeenassociatedwithexcessmor- andriskfactorsformortalityinordertoinformfuturetailored
bidity and mortality (1, 2). A number of studies have interventions.
reportedincidencethatgreatlyexceedsthatofthegeneral Thecurrentstudywasundertakentoassesstheincidence
population(3–5).Riskfactorsthathavebeenassociatedwith ofmortalityandriskfactorsformortalityamongyoungin-
mortalityamonginjectiondrugusers(IDUs)frompriorstudies jectiondrugusersinSanFrancisco,California.Giventhat
includeinfectiousdiseases,suchashumanimmunodeficiency theUFO(‘‘UFindOut’’)Studyhasbeencollectingdetailed
virus (HIV) and hepatitis C virus (HCV) (3, 6–8). Given informationonyoungIDUssincethelate1990s,itprovides
improvementsinmedicalcareforHIVandHCVaswellas auniqueopportunitytostudymortalitytrendsandriskfactors
morewidespreadimplementationofpublichealthinterven- for mortality in this population. The specific aims of the
tionsforIDUs(needleexchange,overdoseprevention,opiate studywereasfollows:1)toinvestigatetrendsinmortality
substitutiontreatment,andsoon),currentstudiesareneeded incidence overall and overdose-specific mortality, 2) to
toassesswhethertheincidenceandcausesofmortalityhave calculatestandardizedmortalityratios,and3)toidentify
shiftedovertime.Additionally,studiesofuniquesubpopula- riskfactorsformortalityinyounginjectorsinSanFrancisco
tionssuchasyoungIDUsareneededtounderstandthepatterns between1997and2007.
302 AmJEpidemiol. 2012;175(4):302–308
MortalityAmongYoungInjectionDrugUsers 303
MATERIALS ANDMETHODS participationindrugtreatmentprogramsinthepast3months
andinthepastweekinwave3.Recentdrugtreatmentpro-
Beginning in 1997, young (<30 years) IDUs in San gramsincludeddrugdetoxification,residentialtreatment,
Franciscohavebeenofferedparticipationinmultiplepro- methadoneorbuprenorphinemaintenance,and12-steppro-
spective studies under variations of the shared title known grams.Risk-relatedexposuresincludeddurationofinjection
astheUFOStudyanddescribedpreviously(9–11).Inbrief, druguse;frequencyofinjection;injectionofheroin,cocaine,
young IDUs were recruited by peer outreach workers fa- methamphetamine,crack,orheroinmixedwithmethamphet-
miliarwithneighborhoodsinSanFranciscowhereyoung amineorcocaine;noninjectioncrackuse;andnonfatalheroin
IDUs congregate, using study invitation cards and flyers, overdose.Overdosewasdefinedasalossofconsciousness
contactswithyouthfriendlyneighborhoodgroupsandcom- whereatleastoneinterventionwasattemptedbyathirdparty.
munityproviders,andwordofmouth.Inclusioncriteriafor
screeningwerethefollowing:1)lessthan30yearsofage; Dataanalysis
2) self reported use ofinjection drugs in the past 30 days,
3) ability to provide informed consent, 4) understanding Wecalculatedmortalityincidenceoverallandbydemo-
spokenEnglishand,after2005,5)self-reportedHCV-negative graphic and risk characteristics reported at the baseline
or unknown status. The UFO Study had 3 waves of data interview.Standardizedmortalityratioswerecalculatedin
collectionbetweenNovember1997andDecember2007.In 3-year intervals adjusting for age, sex, and racebyusing na-
thefirstwavefrom1997to1999,subjectscompletedabaseline tionalmortalitystatisticsfromtheNationalCenterforHealth
screeninginterviewandunderwentcounselingandserologic Statistics.Standardizedmortalityratioswerecalculatedover-
testingforHIV,hepatitisB,andhepatitisCvirus.Subjects all, separately for males and females, and for overdose-
withoutevidenceofacuteorchronichepatitisBvirus(HBV) relateddeathsonly;95%confidenceintervalswerecalculated
infectionorimmunizationtoHBVwereeligibleforenrollment byassumingthattheobserveddeathsfollowedaPoissondis-
inaprospectivestudy ofHBV vaccination (UFO-2Study). tribution.Coxregressionmodelswithtime-varyingcovariates
Startingin2000,subjectswhowereHCVnegativeatthebase- wereusedtoidentifypredictorsofmortality.Survivaltime
linescreeningwereeligibleforenrollmentintotheUFO-3 was defined as the time from initiation of injection (self-
Study.TheUFO-3Studyhad2wavesofrecruitment,from reportedasageatfirstinjecteddrugs)todeath.Giventhat
2000to2002 andfrom2003to2007.Participants were in- subjectswerecurrentinjectorsatthestartofthestudy,data
cludedin this analysis only if they were enrolled prior to werelefttruncated.Subjectsenteredintotheanalysisatthe
December 31, 2007, the end date for searching for death baselinevisit,andtheyremaineduntilthedateofdeathorwere
records.Allresearchprotocolsandinformedconsentwere censoredatDecember31,2007,orthelastinterviewdateif
approvedbytheInstitutionalReviewBoardoftheUniversity thelastinterviewwasafterDecember31,2007.Covariates
ofCalifornia,SanFrancisco. wereincludedinthemultivariatemodeliftheincidencerate
ratioformortalityreachedstatisticalsignificanceatalevel
ofP<0.10inthebivariateanalysisorwerepotentialcon-
Survey instrumentand measures
founders(studywave,age,gender,HCVstatus,andduration
Eligibleconsentingparticipantswereinterviewed,coun- ofinjectiondruguse).Baselinecharacteristicsincludingage,
seled, and tested for antibodies to HCV (anti-HCV) and gender,durationofinjection,andstudywavewereentered
presenceofviremia(HCVRNA)atbaseline.Follow-upin- intothemodelasfixedcovariates.Druguseandinjection-
cludedmonthly‘‘check-ins’’andquarterlystudyvisitsthat riskbehaviors,overdose,andHCVstatuswereenteredas
includedstructuredinterviewstoassessrisk(principallydrug- time-varyingcovariates.Allanalyseswereconductedwiththe
relatedandsexual)exposures,HCVstatus(includinganti- Statastatisticalsoftwarepackage(release11.2;StataCorpLP,
HCVandHCVRNAtesting),andriskreductioncounseling CollegeStation,Texas).
andreferrals.Inthefirstandsecondstudywaves,testingfor
antibodiestoHIVandHBVwasperformedat baselineand
RESULTS
follow-upvisits.DeathswereascertainedthoughtheNational
DeathIndex(NDI)throughtheendof2007.Methodsfor Atotalof644participantscompletedabaselineinterview
establishingamatcharedescribedindetailontheNDIWeb andwereenrolledintheprospectivecohortfromNovember
site(http://www.csc.gov/nchs/ndi.htm).Inbrief,recordsare 1997 to December 2007. The median age was 22.0 years
matchedbyfirstandlastname,dateofbirth,sex,andstateof (interquartilerange(IQR):19.8–25.0),andparticipantshad
birth.CausesofdeathwereobtainedfromtheNDI-Plus.The injectedforamedianof4.0years(IQR:1.7–6.7)atthebase-
underlyingcauseofdeathwasbasedontheInternational lineinterview.Sixty-eightpercentofparticipantsweremale,
ClassificationofDiseases(ICD),TenthRevision.Theprimary and78%wereCaucasian(Table1);47%hadlessthanahigh
outcomeforthisanalysiswasdateofdeathasidentifiedby school education, and 68% reported being homeless or
anNDImatch.Causesofdeathwerereviewed,andoverdose marginallyhoused.Atthemostrecentinterview,thedrug
deathwasdefinedasICD,TenthRevision,codesX42,X44, mostofteninjected inthepast 30 days washeroin (63%)
X62,andY14.Sociodemographicvariablesincludedinthe followedbymethamphetamine(27%);31%reportedinjecting
analyseswereage,gender,race/ethnicity(Caucasianvs.non- everydayinthepastmonth,68%usedasyringeexchangein
Caucasian),educationallevel(lessthanhighschoolvs.high the pastmonth,and32%were anti-HCV positive.
schoolorgreater),recent(past3months)homelessness,and Weidentified38deathsoverthefollow-upperiodthrough
incarceration.Startinginwave2,participantswereaskedabout 2007usingtheNDI.Theoverallmortalityrateover4,167
AmJEpidemiol. 2012;175(4):302–308
304 Evansetal.
Table1. SelectedBaselineSociodemographicandBehavioralCharacteristicsatLastQuarterlyFollow-upVisitforYoungInjectionDrugUsers
intheUFOStudy,SanFrancisco,California,1997–2007
Mortality
Proportion No.of Incidence
Characteristic No. % Rate/1,000 95%CI
Mortality,% Person-Years RateRatio
Person-Years
Overall 644 100.0 5.9 4,167.36 9.12
Studywave
1997–1999 133 20.7 11.3 1,148.92 13.06 1.00 Referent
2000–2002 334 51.9 5.4 2,395.66 7.51 0.55 0.27,1.14
2003–2007 177 27.5 2.8 622.78 8.03 0.80 0.51,1.27
Age,years
15–19 164 25.5 6.7 1,113.37 9.88 1.00 Referent
20–24 292 45.3 5.1 1,902.58 7.88 0.79 0.36,1.76
25–30 188 29.2 6.4 1,151.41 10.42 1.03 0.68,1.55
Gender
Female 204 31.7 4.4 1,383.47 6.51 1.00 Referent
Male 440 38.3 6.6 2,783.89 10.42 1.60 0.76,3.38
Education
Lessthanhighschool 300 47.0 4.3 2,009.27 6.47 1.00 Referent
Highschoolormore 339 53.0 7.1 2,136.13 11.24 1.74 0.88,3.41
Race/ethnicity
Caucasian 502 78.1 5.6 3,261.45 8.45 1.00 Referent
Non-Caucasian 141 21.9 7.1 842.90 11.78 1.39 0.71,3.17
Homeless,past3months
No 207 32.2 4.4 1,322.38 6.81 1.00 Referent
Yes 436 67.8 6.7 2,840.29 10.21 1.50 0.71,3.17
Sexualbehavior
Female 204 31.7 4.5 1,383.47 6.51 1.00 Referent
Heterosexualmale 261 40.5 8.4 1,710.26 12.86 1.89 0.93,3.83
Menwhohavesexwithmen 179 27.8 3.9 1,074.62 6.52 1.00 0.61,1.64
HepatitisCviruspositive
No 433 67.9 4.9 2,782.30 7.55 1.00 Referent
Yes 205 32.1 8.3 1,356.27 12.53 1.66 0.88,3.15
Humanimmunodeficiencyvirus
positive
No 565 95.8 6.4 3,780.08 9.52
Yes 25 4.2 0.0 149.89 0.00
Ageoffirstdruginjection,years
<17 243 37.7 6.6 1,589.72 10.06 1.00 Referent
17–19 217 33.7 6.0 1,452.42 8.95 0.89 0.43,1.84
(cid:1)20 184 28.6 4.9 1,125.22 8.00 0.89 0.60,1.33
Tablecontinues
person-yearsoffollow-upwas9.12(95%confidenceinter- jected most days in the 30 days prior to the most recent
val(CI):6.63,12.53)per1,000person-yearsofobservation. interview,relativetothosewho injectedmethamphetamine
Infemales,themortalityratewas6.51/1,000person-years (incidence rate ratio (IRR) ¼ 3.03, 95% CI: 1.47, 6.23)
ofobservationand,inmales,10.42/1,000person-yearsofob- (Table 1). The incidence of mortality was significantly
servation.Themedianageatdeathwas26years(IQR:23–30), higher in those who reported having an overdose in the
andthemediantimefrominitiationofinjectinguntildeath past3monthscomparedwiththosewhodidnot(IRR¼2.71,
was 7.7 years (IQR: 4.9–11.3). 95%CI:1.35,5.47).Mortalityrateswereelevatedamong
Increasedmortalitywasobservedamongthosewhoidenti- HCV-seropositive individuals compared with negatives
fiedheroinorheroinmixedwithotherdrugsasthedrugin- but did not reach statistical significance (IRR ¼ 1.66,
AmJEpidemiol. 2012;175(4):302–308
MortalityAmongYoungInjectionDrugUsers 305
Table1. Continued
Mortality
Proportion No.of Incidence
Characteristic No. % Rate/1,000 95%CI
Mortality,% Person-Years RateRatio
Person-Years
Durationinjecting,years
(cid:2)2 194 30.2 5.2 1,281.74 7.80 1.00 Referent
>2–5 209 32.5 5.3 1,377.33 7.99 1.02 0.44,2.41
>5 240 37.3 7.1 1,503.37 11.31 1.20 0.82,1.75
Injectedeveryday,pastmonth
No 446 69.3 5.2 2,840.64 8.10 1.00 Referent
Yes 198 30.7 7.6 1,326.72 11.31 1.40 0.73,2.68
Druginjectedmostdays,pastmonth
Speed/methamphetamine 168 26.5 1.2 1,100.15 1.82 1.00 Referent
Heroin/heroinmix 441 69.6 7.9 2,900.47 12.07 3.03* 1.47,6.23
Other 25 3.9 4.0 137.45 7.28 3.08 0.51,18.66
Injectedalone,past3monthsa
No 338 53.7 5.0 2,184.05 7.78 1.00 Referent
Yes 292 46.3 7.2 1,879.04 11.18 1.44 0.76,2.72
Syringeexchange,pastmonth
No 203 32.0 5.4 1,270.33 8.66 1.00 Referent
Yes 432 68.0 6.3 2,833.50 9.53 1.10 0.55,2.22
Everoverdosed
No 391 60.9 4.9 2,519.38 7.54 1.00 Referent
Yes 251 39.1 7.6 1,638.79 11.59 1.54 0.81,2.90
Overdose,past3monthsa
No 563 88.1 4.8 3,595.02 7.51 1.00 Referent
Yes 76 11.9 14.5 539.66 20.38 2.71* 1.35,5.47
Incarcerated,past3monthsa
No 404 63.0 559 2,561.85 8.59 1.00 Referent
Yes 237 37.0 6.8 1,586.35 10.09 1.17 0.62,2.24
Drugtreatment,past3months
(n¼504)b
No 379 75.2 4.0 2,218.70 6.76 1.00 Referent
Yes 125 24.8 6.4 754.29 10.61 1.57 0.67,3.70
Abbreviations:CI,confidenceinterval;UFO,‘‘UFindOut.’’
*P<0.01.
aTimeframeispastyearforparticipantssurveyedin1997–1999.
bDatanotcollectedinwave1.Timeframeispastweekforparticipantssurveyedin2003–2007.
Table2. Age-,Race-,andSex-adjustedStandardizedMortalityRatiosforYoungInjectionDrugUsersinSanFrancisco,California,Using
NationalReference,1999–2007
Overall Females Males
CrudeNational
Year UFOMortality Mortality Adjusted Mortality Adjusted Mortality Adjusted
Rate/1,000 95%CI Rate/1,000 95%CI Rate/1,000 95%CI
Rate/1,000 SMR SMR SMR
Person-Years Person-Years Person-Years
Person-Years
1999–2001 13.1 8.5 15.3 7.6,27.3 7.1 20.0 2.4,72.3 16.1 14.5 6.6,27.6
2002–2004 9.4 8.4 10.6 5.8,17.8 5.9 15.8 3.3,46.1 11.3 9.7 4.9,17.4
2005–2007 7.6 8.1 8.3 4.4,14.3 7.2 19.1 5.2,48.8 7.8 6.7 3.1,12.7
Abbreviations:CI,confidenceinterval;SMR,standardizedmortalityratio;UFO,‘‘UFindOut.’’
AmJEpidemiol. 2012;175(4):302–308
306 Evansetal.
Table3. IncidenceofOverdoseMortalityAmongYoungInjectionDrugUsersinSanFrancisco,California,
1999–2007
Overall Females Males
Year Mortality Mortality Mortality
Rate/1,000 95%CI Rate/1,000 95%CI Rate/1,000 95%CI
Person-Years Person-Years Person-Years
1999–2001 7.1 3.2,15.9 0 10.7 4.8,23.8
2002–2004 6.0 3.1,11.6 2.0 0.3,13.9 8.2 4.1,16.4
2005–2007 4.1 2.0,8.6 1.8 0.3,12.7 5.2 2.3,11.6
Abbreviation:CI,confidenceinterval.
95%CI:0.88,3.15)atP<0.05.Mortalityincidencedidnot healthinterventionsthataddresstheriskofoverdoseinthis
differbyage,race/ethnicity,everhavingoverdosed,duration population inordertoreduce premature deaths.
ofinjection,orincarcerationinthepast3months. TheoverallmortalityrateobservedinthisstudyofIDUs
Byuseofnationalmortalityasthereference,theover- inSanFranciscowas9.12per1,000person-yearsofobser-
all adjusted standardized mortality ratio for 1999–2001 vation. Another study of young and recent-onset injectors
was 15.3 (95% CI: 7.6, 27.3), which decreased to 10.6 thatincludeddatafrom5differentcitiesintheUnitedStates
(95%CI:5.8,17.8)in2002–2004and8.3(95%CI:4.4,14.3)
in2005–2007(Table2).Whendatawerestratifiedbywave
ofrecruitment,temporaldeclinesinmortalitypersisted(data
Table4. MultivariateCoxProportionalHazardsModelof
notshown).Infemales,theadjustedstandardizedmortality
IndependentPredictorsofMortalityAmongYoungInjectionDrug
ratioswerehigherthaninmalesacrossalltimebands.Further-
UsersinSanFrancisco,California,1997–2007a
more,theredidnotappeartobeatrendtowardadecreasing
standardizedmortalityratioovertimeamongwomen,asthere Adjusted
Characteristic 95%CI PValue
appearedtobeformen.Incidenceofoverdosemortalityalso HazardRatio
declinedbetween2000and2007(Table3).However,women Studywave
hadlowerratesofoverdosemortalitycomparedwithmen, 1997–1999 1.00 Referent
andtheirratesdidnotappeartodecline.Theprincipalcause
2000–2002 0.83 0.39,1.75 0.62
of death for the overall cohort was overdose (57.9%), fol-
2003–2007 0.82 0.28,2.42 0.72
lowed by self-inflicted injuries (13.2%), other drug-related
medicalconditions(13.2%),traumaoraccidents(10.5%), Age,years 1.00 0.89,1.11 0.98
and other causes (5.3%). Durationinjecting,years
InCoxregressionwithtime-varyingcovariatesadjusting (cid:2)2 1.00 Referent
forageanddurationinjecting,participantswhousedheroin
>2–5 0.94 0.35,2.51 0.90
orheroinmixmostdaysorwhohadarecentoverdosehad
>5 1.50 0.42,5.36 0.54
elevatedmortality(Table4).Ofthesefactors,heroin/heroin
Gender
mix as the drug used most days in the pastmonth was the
onlyoneindependentlyassociatedwithmortality(adjusted Female 1.00 Referent
hazardratio¼5.76,95%CI:1.37,24.30)(P<0.05).Having Male 1.62 0.73,3.58 0.24
arecentnonfataloverdosewasassociatedwithhigherrelative HepatitisCvirusstatus
hazardsofdeath,althoughthisdidnotquitemeetstatistical
Negative 1.00 Referent
significance.Afteradjustmentforothercovariates,being
Positive 1.36 0.68,2.70 0.39
HCVinfectedwasnotsignificantlyassociatedwithincreased
relativehazards ofdeath. Druginjectedmostdays
inpastmonth
Methamphetamine 1.00 Referent
DISCUSSION Heroin/heroinmix 5.76 1.37,24.30 0.02
Other 3.52 0.31,39.44 0.31
ThisstudyofyoungIDUsinSanFranciscobetween1997
and2007foundoverallmortalityrates10timeshigherthan Overdosed,past
3monthsb
thoseinthegeneralpopulation.Mortalityappearedtodecline
overthe10-yearperiod;however,stratifiedresultssuggested No 1.00 Referent
thatdeclineswererestrictedtomales.Theleadingcauseof Yes 1.92 0.91,4.06 0.09
deathinthiscohortwasoverdose,andprimaryuseofheroin
Abbreviation:CI,confidenceinterval.
wastheonlysignificantindependentriskfactorfordeaththat
aIncludesallvariablesassociatedatP<0.10inbivariateanalyses
wasobservedinthestudy.Together,thesefindingshighlight
andadjustingforage,durationinjecting,gender,hepatitisCvirus
thesubstantialmortalityriskassociatedwithinjectingdrugs status,andstudywave.
for youngpersons and pointtoa continuedneed forpublic bTimeframeispastyearforparticipantssurveyedin1997–1999.
AmJEpidemiol. 2012;175(4):302–308
MortalityAmongYoungInjectionDrugUsers 307
foundasimilarmortalityrate(3).Thatstudyfoundaninitial mortality(3,6).Thisdifferencecanlikelybeexplainedby
increaseofmortalityinthe 2 yearsofthe cohortstudy, fol- therelativelysmallabsolutenumberofparticipantsincluded
lowedbyadecrease,whichledtheauthorstohypothesize in oursampleand the small numberof persons with HIV.
thattheimmediateyearsfollowinginitiationofdrugusemight Also,HIVasacauseofdeathhasbeenshowntohavepeaked
beaperiodofhigherrisk.Incontrast,ourstudyfoundonly inthe1990s(20,21),beforetheadventofhighlyactiveanti-
acontinuousdeclineinmortalityovercalendarperiods.The retroviraltherapy,andislesslikelytoimpactmortalityin
priorstudybyVlahovetal.enrolledonlyrecentlyinitiated young versusolder injectors (7).
IDUs(<5years)andthereforedidnotincludearangeofage Ourstudyshoweddifferencesindeathratesbetweenmen
anddurationofdrugusetoclarifyperiodeffects.Ourstudy and women. Although the incidence of death was higher
includedparticipantswithawiderangeofinjectingexposure amongmencomparedwithwomen,standardizedmortality
time(median¼4years,IQR:1.7–6.7),andweperformed ratioswerehigherforwomen.Femaleinjectorswere12times
multivariateCoxmodelstoanalyzetheindependenteffects more likely to die compared with females in the general
ofageanddurationofuse.Theresultsdidnotsupportan USpopulation;incontrast,maleinjectorswere8timesmore
association between duration of use and mortality. likelytodiecomparedwiththemaleUSpopulation.Asimilar
Thereareseveralpotentialexplanationsfortheobserved differenceinsex-stratifiedstandardizedmortalityratioshas
decline in mortality in our cohort of young injectors. First, beenreportedinacohortofyoungIDUsinCanada(6).In
it is possible that public health interventions could have addition,althoughratesofdeathappearedtodeclineover
ledtofewerdeathsovertheyears.Inthepastdecade,several timeamongmen,ratesappearedrelativelystableforwomen
overdosepreventionprogramshavebeenimplementedinthe over the 10-year period. Sex-stratified results should be
United States including the distribution of the overdose- interpreted with caution however,as the sample sizewas
reversaldrug,opiateantagonistnaloxone(NARCAN;Endo relativelysmallandresultedinwideconfidenceintervalsfor
Pharmaceuticals,Inc.,ChaddsFord,Pennsylvania),toIDUs period-specificmortalityrates.
(12–16).Oneofthelongestrunningnaloxoneprescription Therewereanumberofimportantlimitationstothisstudy.
programs in the United States was implemented in San Mortalityratesmaybeunderestimatesbecauseofdeathsthat
Franciscoin2003andhasprovidedoverdosepreventiontrain- werenotcapturedbytheNDIsearchcriteria.Anumberof
ingandprescribednaloxonetonearly2,000individualsas studyparticipantswerebelievedtohavegivenpseudonyms
of December 2009 (16). Furthermore, improved access to ratherthanbirthnames,whichwouldnotallowmatching,and
treatmentforopioiddependencemaybeafactor,asopioid incorrectbirthdatesmayhavebeengiven.Causesofdeath
substitutiontreatmentinIDUshasbeenshowntobeasig- werebasedonICDcodesondeathcertificatesthatmaybe
nificantfactorinreducingtheriskofmortality(17).There inaccurate(22).Analysesusedbaselinepredictordata,and
could have been a change in the purity of heroin over the somecovariatesmeasuredconstructsthatcouldchangeover
years(18).Finally,becausetherewasongoingenrollmentof time(HIVandHCVinfections,injectingbehaviors,incarcer-
ourcohort,differencesinmortalityovertimemaybeassoci- ation,andsoon).Therefore,analysesofcertainpredictors
atedwithunmeasureddifferencesintheUFOStudypopulation should be interpreted with caution. Finally, the relatively
over time,such that subjects with lower riskwere recruited modestsamplesizeandsmallabsolutenumberofdeathsare
duringlaterphasesofthestudy.Totestthishypothesis,we limitations,particularlywithregardtosex-stratifiedresults.
includedavariableforperiodofstudyrecruitmentinour Inconclusion,thisstudyofyoungIDUsinSanFrancisco
Coxmodels.Althoughwedidnotfindsignificantdifferences demonstratedthatinjectiondruguseisassociatedwithsub-
inthehazardratiosfordeathbyenrollmentwave,thehazard stantiallyincreasedriskfordeath,andthatmostoftheexcess
ratios were less than 1.0 comparing the later with earlier riskisduetooverdoseandtrauma.Resultsalsosuggestthat,
years, suggesting that this could be an underlying factor. among young adult injectors in San Francisco, mortality
Furthermore,whenweinvestigatedchangesintheUFOStudy ratesaredecreasingovertimebutaregenerallyrestricted
populationacrossthe3wavesofdatacollection,wefound tomales.Researchisneededtoconfirmtheseresultsand
thatparticipantsinthefirstwaveweremorelikelytoinject explorereasonsforsex-specificdifferencesinmortalityin
heroinorheroinmixedwithotherdrugsinthepastmonthand young IDUs.
were significantly less likely to inject methamphetamine
in the past month at baseline (data not shown). Since pri-
mary use of heroin as the drug of injection was strongly
ACKNOWLEDGMENTS
predictiveofdeathinourCoxmodels(hazardratio¼5.76,
95%CI:1.37,24.30),thisobserveddeclineinheroininjection Author affiliations: Department of Epidemiology and
inlaterwavesofstudyrecruitmentisalikelycontributorto Biostatistics,UniversityofCalifornia,SanFrancisco,San
the decline in overdose mortality over time. Francisco,California(JenniferL.Evans,KimberlyPage);
Ourstudyofyounginjectiondrugusersfoundthemost Department of Medicine, University of California, San
commoncausesofdeathtobeoverdoseandtrauma,which Francisco, San Francisco, California (Judith A. Hahn,
isconsistentwithpriorstudies(3,6,7,19).Thissupports PaulaJ.Lum);SchoolofMedicine,BostonUniversity,Boston,
acontinuedfocusonoverdosepreventioninthisagegroup. Massachusetts (Judith I. Tsui); and Department of Med-
Oftheriskfactorsexaminedinthisstudy,onlyuseofheroin icine, University of California, San Diego, San Diego,
as the main injecting drug was independently predictive of California (Peter J. Davidson).
death. This contrasts with 2 prior studies of young IDUs Thisresearchwasconductedwiththesupportofagrantfrom
thatfoundHIVinfectiontobesignificantlyassociatedwith theNationalInstituteonDrugAbuse(5R01DA016017-08).
AmJEpidemiol. 2012;175(4):302–308
308 Evansetal.
The authors would like to thank the UFO Study Field Francisco,Calif:theUFOStudy.AmJPublicHealth.2003;
Stafffortheirtimeanddedicationinconductingthestudy. 93(6):919–923.
Conflict ofinterest:none declared. 11. PageK,HahnJA,EvansJ,etal.AcutehepatitisCvirus
infectioninyoungadultinjectiondrugusers:aprospective
studyofincidentinfection,resolution,andreinfection.JInfect
Dis.2009;200(8):1216–1226.
REFERENCES 12. SealKH,ThawleyR,GeeL,etal.Naloxonedistribution
andcardiopulmonaryresuscitationtrainingforinjectiondrug
1. DegenhardtL,HallW,Warner-SmithM.Usingcohortstudies userstopreventheroinoverdosedeath:apilotintervention
toestimatemortalityamonginjectingdrugusersthatisnot study.JUrbanHealth.2005;82(2):303–311.
attributabletoAIDS.SexTransmInfect.2006;82(suppl3): 13. BacaCT,GrantKJ.Take-homenaloxonetoreduceheroin
iii56–iii63. death.Addiction.2005;100(12):1823–1831.
2. HulseGK,EnglishDR,MilneE,etal.Thequantification 14. MaxwellS,BiggD,StanczykiewiczK,etal.Prescribing
ofmortalityresultingfromtheregularuseofillicitopiates. naloxonetoactivelyinjectingheroinusers:aprogramto
Addiction.1999;94(2):221–229. reduceheroinoverdosedeaths.JAddictDis.2006;25(3):89–96.
3. VlahovD,WangC,OmpadD,etal.Mortalityriskamong 15. ShermanSG,GannDS,TobinKE,etal.‘‘Thelifetheysave
recent-onsetinjectiondrugusersinfiveU.S.cities.Collabo- maybemine’’:diffusionofoverdosepreventioninformation
rativeInjectionDrugUserStudy.SubstUseMisuse.2008; fromacitysponsoredprogramme.IntJDrugPolicy.2009;
43(3-4):413–428. 20(2):137–142.
4. BargagliAM,HickmanM,DavoliM,etal.Drug-related 16. EnteenL,BauerJ,McLeanR,etal.Overdoseprevention
mortalityanditsimpactonadultmortalityineightEuropean andnaloxoneprescriptionforopioidusersinSanFrancisco.
countries.COSMOEuropeanGroup.EurJPublicHealth. JUrbanHealth.2010;87(6):931–941.
2006;16(2):198–202. 17. KimberJ,CopelandL,HickmanM,etal.Survivaland
5. DegenhardtL,BucelloC,MathersB,etal.Mortalityamong cessationininjectingdrugusers:prospectiveobservational
regularordependentusersofheroinandotheropioids: studyofoutcomesandeffectofopiatesubstitutiontreatment.
asystematicreviewandmeta-analysisofcohortstudies. BMJ.2010;340:c3172.(doi:10.1136/bmj.c3172).
Addiction.2011;106(1):32–51. 18. CunninghamJK,MaxwellJC,CampolloO,etal.Proximity
6. MillerCL,KerrT,StrathdeeSA,etal.Factorsassociated totheUS-Mexicoborder:akeytoexplaininggeographic
withprematuremortalityamongyounginjectiondrugusers variationinUSmethamphetamine,cocaineandheroinpurity.
inVancouver.HarmReductJ.2007;4:1.(doi:10.1186/1477- Addiction.2010;105(10):1785–1798.
7517-4-1). 19. WebbL,OyefesoA,SchifanoF,etal.Causeandmannerof
7. ClausenT,WaalH,ThoresenM,etal.Mortalityamongopiate deathindrug-relatedfatality:ananalysisofdrug-related
users:opioidmaintenancetherapy,ageandcausesofdeath. deathsrecordedbycoronersinEnglandandWalesin2000.
Addiction.2009;104(8):1356–1362. DrugAlcoholDepend.2003;72(1):67–74.
8. GossopM,StewartD,TreacyS,etal.Aprospectivestudyof 20. CopelandL,BuddJ,RobertsonJR,etal.Changingpatternsin
mortalityamongdrugmisusersduringa4-yearperiodafter causesofdeathinacohortofinjectingdrugusers,1980–2001.
seekingtreatment.Addiction.2002;97(1):39–47. ArchInternMed.2004;164(11):1214–1220.
9. HahnJA,Page-ShaferK,LumPJ,etal.HepatitisCvirus 21. VlahovD,WangCL,GalaiN,etal.Mortalityriskamongnew
seroconversionamongyounginjectiondrugusers:relationships onsetinjectiondrugusers.Addiction.2004;99(8):946–954.
andrisks.JInfectDis.2002;186(11):1558–1564. 22. NielsenGP,Bjo¨rnssonJ,JonassonJG.Theaccuracyof
10. LumPJ,OchoaKC,HahnJA,etal.HepatitisBvirus deathcertificates.Implicationsforhealthstatistics.Virchows
immunizationamongyounginjectiondrugusersinSan ArchAPatholAnatHistopathol.1991;419(2):143–146.
AmJEpidemiol. 2012;175(4):302–308
